PER (PER) News
Track canonical SquawkNews coverage tagged to PER, PER. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Peruvian Metals Corp. (TSXV:PER) Starts Underground Development at Palta Dorada
Peruvian Metals Corp. began underground development at its 100% owned Palta Dorada gold-silver property in Peru to access sulphides, with material to be processed at its Aguila Norte plant.Material DetailsContext by AI A
COMMODITIES | Sep 15, 2026, 12:01 PM UTC
L
Peruvian Metals Corp. Commences Underground Development to Access High-Grade Au-Ag Sulphides at Palta Dorada
Edmonton, Alberta--(. - September 15, 2026) - Peruvian Metals Corp TSXV:PER (OTC Pink: DUVNF) ("Peruvian Metals" or the "Company") is pleased to announce that the Company has commenced underground development at its 100%
COMMODITIES | Sep 15, 2026, 12:01 PM UTC
L
Peruvian Metals reports positive tailings samples and 2026 outlook
Peruvian Metals says it completed a major overall and maintenance program at its Aguila Norte processing plant and reports positive sample results from the tailings area, citing a full production outlook for 2026.
EQUITY | Sep 08, 2026, 01:06 PM UTC
L
Edison issues report on Percheron Therapeutics clinical strategy
TradingView reports Edison issued a report on Percheron Therapeutics, highlighting an investigator-sponsored exploratory study of HMBD-002 in acute myeloid leukaemia (AML).
EQUITY | Sep 04, 2026, 09:06 AM UTC
M
Percheron Therapeutics firm commitments for A$2.3 million placement
Percheron Therapeutics received firm commitments for an institutional placement of A$2.3 million.
EQUITY | Sep 01, 2026, 01:31 AM UTC
M
Percheron Therapeutics to trial Hmbd-002 in acute myeloid leukemia
Percheron Therapeutics says Vanderbilt Health will conduct a clinical trial of Hmbd-002 in acute myeloid leukemia.
EQUITY | Aug 28, 2026, 01:32 AM UTC
H
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
GEOPOLITICS | Jun 26, 2026, 12:01 PM UTC